Literature DB >> 15750270

Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.

Mototsugu Takashima1, Naoya Igaki, Tomokazu Matsuda, Minako Ohyama, Suirin Kanda, Fumihiko Tamada, Takeo Goto.   

Abstract

We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after previous failed extensive therapy, including multiple surgeries and hepatic artery embolization. Within a few months of starting administration of imatinib mesylate, the patient exhibited a clinical response with grade 3 neutropenia, when pulmonary tuberculosis developed. A c-kit mutation in exon 11 was detected only in metastatic liver specimens. It is unclear whether or not pulmonary tuberculosis may be induced by imatinib mesylate treatment, but caution is warranted in immunocompromised GIST patients. This is the first report of tuberculosis associated with neutropenia during imatinib mesylate treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750270     DOI: 10.2169/internalmedicine.44.114

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages.

Authors:  Heiko Bruns; Frank Stegelmann; Mario Fabri; Konstanze Döhner; Ger van Zandbergen; Manfred Wagner; Mhairi Skinner; Robert L Modlin; Steffen Stenger
Journal:  J Immunol       Date:  2012-09-17       Impact factor: 5.422

Review 3.  Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.

Authors:  Bettina M Knoll; K Seiter
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553

4.  Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.

Authors:  Abbas Agaimy; Valeska Brueckl; Daniela Schmidt; Stephanie Krieg; Evelyn Ullrich; Norbert Meidenbauer
Journal:  Case Rep Oncol       Date:  2013-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.